Delving into the Latest Updates on Respiratory Syncytial Virus Vaccine (GENEVAX) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, Genetically engineered subunit vaccine

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious Diseases

Active Indication

Respiratory Syncytial Virus Infections

Inactive Indication-

Originator Organization

Beijing Jinuo Sanitary Technology Co., Ltd.

Active Organization

GENEVAX (Hebei) Biotechnology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The primary objective is to evaluate the safety of recombinant respiratory syncytial virus vaccine (CHO cells) in people aged 18-59 years and people aged ≥60 years; the secondary objective is to evaluate the humoral immune response, immune persistence and cellular immune response; the exploratory objective is to evaluate the level of anti-Ferritin protein antibodies after vaccination.

Start Date-

Sponsor / Collaborator

Beijing Jinuo Sanitary Technology Co., Ltd.

[+2]

100 Clinical Results associated with Respiratory Syncytial Virus Vaccine (GENEVAX)

Login to view more data

100 Translational Medicine associated with Respiratory Syncytial Virus Vaccine (GENEVAX)

Login to view more data

100 Patents (Medical) associated with Respiratory Syncytial Virus Vaccine (GENEVAX)

Login to view more data

100 Deals associated with Respiratory Syncytial Virus Vaccine (GENEVAX)

Login to view more data